Navigation Links
SNM applauds FDA advisory committee recommendation for approval of Alzheimer's imaging agent
Date:1/24/2011

Reston, Va. (January 21, 2011) The Society of Nuclear Medicine (SNM) commends the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee on its recent recommendation for conditional approval of a new imaging agent, florbetapir. The agent, which is used in conjunction with positron emission tomography (PET) scans to detect beta amyloid plaques of the brain which may cause Alzheimer's disease, is produced by Eli Lilly and Company under the name Amyvid.

"For many years, the in vivo diagnosis of Alzheimer's disease has been a process of exclusion of other disorders that may affect cognition," said Karl Herholz, MD, president of SNM's Brain Imaging Council. "Now, for the first time, PET scans utilizing florbetapir will provide disease-specific inclusion criteria in the in vivo diagnosis of the disease."

PET scans performed with florbetapir will allow physicians to provide prognostic information to patients and their families even at a time of limited therapeutic approaches to treat Alzheimer's disease. In addition, the availability of imaging agents that can reliably detect amyloid plaques will be an absolute prerequisite to select patients that may benefit from future specific anti-amyloid based Alzheimer therapies.

"This recommendation of florbetapir is a huge step forward for the field of molecular imaging," noted Carolyn J. Anderson, PhD, president of SNM's Center for Molecular Imaging Innovation and Translation. "Researchers are continually working to advance the adoption of emerging molecular imaging technologies and probes in preclinical and clinical applications. It's wonderful to see molecular imaging playing such an important role in the molecular characterization of Alzheimer's disease. We are hopeful that this sets the stage for the approval of the many other molecular imaging agents for cancer, cardiovascular disease and other neurological diseases that are currently in clinical trials."

The FDA advisory committee approved florbetapir by a vote of 16-0 on the condition that training is provided to ensure physicians read the PET scans consistently and correctly. SNM and its Brain Imaging Council, in collaboration with other professional societies, are committed to developing PET imaging procedure guidelines and diagnostic scan interpretation educational tools to ensure that nuclear medicine physicians and radiologists will be proficient in performing and interpreting PET scans used in the diagnosis of Alzheimer's disease.

The FDA may or may not accept the opinion of the advisory committee.


'/>"/>

Contact: Susan Martonik
smartonik@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. SNM applauds US Senates introduction of CARE Act
2. National Council Applauds Rep. Tonko for Seeking Strict Enforcement of Mental Health Parity Law – July 1, 2010 Deadline Approaching
3. Life Line Screening Applauds Rep. Paulsen on P.A.D. Resolution
4. ASTRO applauds MedPAC review of Stark law exception
5. ASTRO applauds nomination of Dr. Donald Berwick to head Centers for Medicare and Medicaid Services
6. SNM applauds temporary freeze on Medicare cuts
7. The Arc Applauds House Passage of Health Care Reform Legislation
8. Pew Applauds Federal Grant Program Supporting State Expansion of Evidence-Based Home Visitation
9. National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Reconciliation Bill
10. ISSA Applauds Cincinnati Trainer Anthony Reed for Dedication to Health Awareness
11. First Personal Injury Applauds HSE Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... for Global Policy Solutions is vehemently opposed to Donald Trump’s budget, “A New ... for despair that inspires fear, demonizes the poor, marginalizes underserved populations, undermines productivity, ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Curry ... the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. As a compassionate and ... his field by attending numerous CE courses each year. His recent course, Course ...
(Date:5/24/2017)... Utah (PRWEB) , ... May 24, 2017 , ... ... Sick Kids: The Surprising Truth about Pediatric Septic Shock” hosted by the Journal of ... 2017, at 2 p.m. Eastern time, will be presented by Captain Rommie Duckworth, LP, ...
(Date:5/24/2017)... Soquel, California (PRWEB) , ... May 24, 2017 , ... If you are thinking of ... you are interested in business architecture, October is the perfect time to visit. , Business ... as an à la carte offering for individuals, as a 4-½ day package for individuals, ...
(Date:5/24/2017)... ... ... Rob Lowe is a sought after actor, and also serves as the host of ... from all aspects of life, and a new segment is being developed on podiatry, ... Podiatry is essential to people’s overall well-being, and if viewers have feet problems, they ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based in ... Parkinson,s disease (PD), has enrolled the first patient in the ... multicenter study involving patients with PD and taking place at ... 9-to-12-month period. The first stage is open label and involves ... include Denver , Boca Raton ...
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
(Date:5/10/2017)... Ill. , May 10, 2017 Radiology ... today; unfortunately its costs have also spiraled to the ... being sent to radiology than ever before as the ... diagnosis.  For a patient with lower back pain an ... no anatomical reason for pain, resulting in entirely different ...
Breaking Medicine Technology: